Hyperparathyroidism Treatment Market to Reach $1.35B by 2032 | Parathyroid Hormone Dominates with 55.8% Share | North America Leads with 38.4% Market| DataM Intelligence

Leander, Texas-The global hyperparathyroidism treatment market was valued at $835.5 million in 2025 and is projected to reach approximately $1.35 billion by 2032, growing at a CAGR of 7.1% during this period.The market is driven by rising prevalence of chronic kidney disease, increasing geriatric population, and greater awareness of early diagnosis and treatment options.

Download your exclusive sample report today: (corporate email gets priority access):https://www.datamintelligence.com/download-sample/hyperparathyroidism-treatment-market?pratik

🔹 United states industry development
⇥ U.S. market size was USD 4.34 billion in 2018; projected to reach about USD 9.88 billion by 2032 with CAGR 7.5% (2019-2032).

⇥ Southern U.S. leads market share due to high dialysis rates and presence of major clinics (Fresenius, DaVita).

⇥ Home dialysis and online channel usage for SHPT treatment rising; generics boosting market penetration.

⇥ Medicare (Part B) covers main therapies, enhancing access; Vitamin D analogues are top treatment segment.

⇥ Ongoing collaborations and new generic SHPT drugs drive expansion.

🔹 Japan industry development
⇥ Japan's SHPT treatment market size was USD 0.4 billion in 2024, projected to reach USD 0.6 billion by 2032.

⇥ Growing demand for novel therapies, supported by pharma companies like Kyowa Kirin and Taisho Pharmaceutical.

⇥ Sophisticated healthcare infrastructure and aging population drive market growth.

⇥ Investment in R&D and digital treatment models promoted by government policies; increase in early diagnosis.

⇥ Market supported by expanded awareness of calcium disorders and CKD, boosting access to advanced treatment

🔹 Market segmentation with Market share -

⇥By Product

Parathyroid hormone - 55.8%
(Dominates due to targeted treatment mechanism not found in other products)

Vitamin D analogs - 30%
(Widely used for managing calcium balance in hyperparathyroidism)

Calcimimetics - 12% (approximate)
(Significant growth segment, drugs like Cinacalcet lower parathyroid hormone effectively)

Others (phosphate binders etc.) - Remainder

⇥By Route of Administration

Oral administration - 54.4%
(Preferred for convenience and patient compliance)

Parenteral (IV) - 45.6%
(Used in hospital/clinical settings for advanced cases)

"Secure your 30% year-end discount - get this report before the offer expires."
:https://www.datamintelligence.com/buy-now-page?report=hyperparathyroidism-treatment-market?pratik ((Purchase 2 or more Repots and get 50% Discount)

🔹 Regional insights-

➠ North America:

38.4% share of the global hyperparathyroidism treatment market.

Dominated by the U.S. and Canada due to well-established healthcare infrastructure, high disease awareness, and strong investment in diagnostics and treatment.

Key players (e.g., Amgen, Eli Lilly) are headquartered here, fueling R&D activity.

➠ Asia‐Pacific:

Identified as the fastest-growing region for hyperparathyroidism treatment.

Growth drivers include rising healthcare expenditure, improving access to medical care, and increasing disease awareness.

➠ Europe:

Europe is the second-largest regional market (after North America) for hyperparathyroidism treatment.

Growth is driven by the increasing prevalence of hyperparathyroidism, particularly in aging populations

🔹 Emerging players in the geopolymer market :-

⇥OPKO Health, Inc. - Emerging with about 10% market share; known for innovative extended-release therapies like Rayaldee and clinical advancements in vitamin D analogs.

⇥Pathalys Pharma - Holds approximately 5% market share; focused on novel drug candidates with targeted mechanisms improving treatment efficacy and safety profiles.

⇥Vifor Pharma AG - Around 7% share; strong in calcimimetics and partnerships enhancing treatment access and portfolio expansion globally.

⇥Mitsubishi Tanabe Pharma - Captures near 4% market share; investing in R&D for next-gen therapies with an emphasis on the Asian markets including Japan.

⇥Shanghai Hengrui Pharmaceutical - Growing player with around 3-4% share; actively developing calcimimetic agents and conducting late-stage clinical trials in China and globally.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/hyperparathyroidism-treatment-market?pratik

🔹 Key Investment:
➠ OPKO Health, Inc. (U.S.): Invested over USD 80 million in expanding Rayaldee production and late-stage clinical trials for SHPT treatment, highlighting confidence in extended-release therapies.

➠ BridgeBio Pharma, Inc. (U.S.): Raised USD 60 million in 2025 for development of small-molecule drugs like Encaleret targeting post-surgical hypoparathyroidism, enabling pipeline diversification.

➠ Shanghai Hengrui Pharmaceutical Co., Ltd. (China): Committed USD 50 million toward calcimimetic SHR6508 clinical programs, strengthening presence in Asian and global hyperparathyroidism markets.

➠ Takeda Pharmaceutical Company Limited (Japan): Allocated USD 40 million to advanced recombinant PTH therapies and digital health platforms for treatment optimization, increasing innovation footprint.

🔹 Growth Drivers:-

➠ Increasing prevalence of hyperparathyroidism, especially in aging populations, drives demand for treatment solutions.

➠ Rising cases of chronic kidney disease (CKD) and associated secondary hyperparathyroidism boost market growth.

➠ Advances in early diagnosis and minimally invasive surgeries improve treatment adoption.

➠ Development and adoption of novel therapies like calcimimetics, vitamin D analogs, and parathyroid hormone treatments enhance efficacy and patient compliance.

➠ Growing awareness and healthcare investments in emerging markets increase access and demand.

➠ Expansion of digital healthcare and telemedicine facilitates remote monitoring and treatment accessibility.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?pratik

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insightsthrough pricing analysis, market share breakdowns, and competitive intelligence. Thecompany specializes in strategic reports that guide businesses in high-growth sectors suchas nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter,LinkedIn and Facebook.

This release was published on openPR.